Skip to main content
. 2015 Jun 25;6(6):e94. doi: 10.1038/ctg.2015.18

Figure 5.

Figure 5

Dose response for mean pH ≥4 holding time ratio (left) and pH ≥5 holding time ratio (right) in the phase I, randomized, double-blind, placebo-controlled, Japanese and UK single rising-dose studies in healthy male subjects receiving a single TAK-438 dose (1–120 mg in Japan and 1–40 mg in the UK; pharmacodynamic analysis set; Japan N=82, UK N=63).